Search

Your search keyword '"Surewicz K"' showing total 62 results

Search Constraints

Start Over You searched for: Author "Surewicz K" Remove constraint Author: "Surewicz K"
62 results on '"Surewicz K"'

Search Results

6. Human prion protein variant V129

12. Pathological C-terminal phosphomimetic substitutions alter the mechanism of liquid-liquid phase separation of TDP-43 low complexity domain.

13. Influence of the Dynamically Disordered N-Terminal Tail Domain on the Amyloid Core Structure of Human Y145Stop Prion Protein Fibrils.

14. 13 C and 15 N chemical shift assignments of A117V and M129V human Y145Stop prion protein amyloid fibrils.

15. Regulatory mechanisms of tau protein fibrillation under the conditions of liquid-liquid phase separation.

16. Zinc promotes liquid-liquid phase separation of tau protein.

17. Liquid-liquid phase separation of tau protein: The crucial role of electrostatic interactions.

18. The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain.

19. Protein-solvent interfaces in human Y145Stop prion protein amyloid fibrils probed by paramagnetic solid-state NMR spectroscopy.

20. Conformational Dynamics in the Core of Human Y145Stop Prion Protein Amyloid Probed by Relaxation Dispersion NMR.

21. Structural Studies of Amyloid Fibrils by Paramagnetic Solid-State Nuclear Magnetic Resonance Spectroscopy.

22. Artificial strain of human prions created in vitro.

23. Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.

24. Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.

25. Species-dependent structural polymorphism of Y145Stop prion protein amyloid revealed by solid-state NMR spectroscopy.

26. Self-propagating, protease-resistant, recombinant prion protein conformers with or without in vivo pathogenicity.

27. 13 C and 15 N chemical shift assignments of mammalian Y145Stop prion protein amyloid fibrils.

28. Amyloid fibrils from the N-terminal prion protein fragment are infectious.

29. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.

30. Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-β Oligomers Causing Cytotoxicity Inhibition.

31. Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β.

32. Interaction between prion protein and Aβ amyloid fibrils revisited.

33. Thermodynamic stabilization of the folded domain of prion protein inhibits prion infection in vivo.

34. Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity.

35. Small protease sensitive oligomers of PrPSc in distinct human prions determine conversion rate of PrP(C).

36. Structural polymorphism in amyloids: new insights from studies with Y145Stop prion protein fibrils.

37. Intermolecular alignment in Y145Stop human prion protein amyloid fibrils probed by solid-state NMR spectroscopy.

38. Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors.

39. Conformational flexibility of Y145Stop human prion protein amyloid fibrils probed by solid-state nuclear magnetic resonance spectroscopy.

40. Conformational diversity in prion protein variants influences intermolecular beta-sheet formation.

41. The role of glycophosphatidylinositol anchor in the amplification of the scrapie isoform of prion protein in vitro.

42. Antimicrobial activity of human prion protein is mediated by its N-terminal region.

43. Nanomechanical properties of human prion protein amyloid as probed by force spectroscopy.

44. Molecular conformation and dynamics of the Y145Stop variant of human prion protein in amyloid fibrils.

45. Role of N-terminal familial mutations in prion protein fibrillization and prion amyloid propagation in vitro.

46. The effect of disease-associated mutations on the folding pathway of human prion protein.

47. The differential interaction of p38 MAP kinase and tumor necrosis factor-alpha in human alveolar macrophages and monocytes induced by Mycobacterium tuberculois.

48. Macrophage-activating cytokines in human immununodeficiency virus type 1-infected and -uninfected patients with pulmonary tuberculosis.

49. Differential activation of MAP kinase signaling pathways and nuclear factor-kappaB in bronchoalveolar cells of smokers and nonsmokers.

50. Mechanisms of I(Ks) suppression in LQT1 mutants.

Catalog

Books, media, physical & digital resources